Yueyin Pan

A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.

Zefei Jiang, Tao Sun, Xiaojia Wang et al. · Journal of Clinical Oncology · 2022 · 36 citations

Medicine, Medicinal Chemistry, Pharmacology +15

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Ying Cheng, Liang Han, Lin Wu et al. · Journal of Clinical Oncology · 2022 · 35 citations

Medicine, Oncology, Pharmacology +17

CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

Jia Liu, Jianwei Yang, Yuping Sun et al. · Nature Medicine · 2025 · 31 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Efficacy, Safety, and Immunogenicity of HLX04Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatmentfor Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase IIIStudy

Shukui Qin, Jin Li, Wei Li et al. · BioDrugs · 2021 · 29 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Prognostic role of LSD1 in various cancers: evidence from a meta-analysis

Yueyin Pan, Jin Wu, Lixia Hu et al. · OncoTargets and Therapy · 2015 · 28 citations · Full text

Medicine, Cancer Biology, Oncology +10